NY-AQARA
27.2.2024 14:01:39 CET | Business Wire | Press release
Aqara, a leading provider of smart home solutions, is excited to initiate the crowdfunding campaign for its latest home access solution, the Smart Lock U200, on Kickstarter. Designed for flexibility, convenience and security, the U200 lock is built upon the latest Thread protocol and natively Matter-enabled, aiming for effortless integration with the widest range of smart home devices across systems and brands1.
At its core, the Aqara U200 utilizes modern engineering crafted to provide users with numerous secure access options, ranging from fingerprints, one-time and recurring PIN codes, remote access via mobile apps, voice assistant commands to Aqara NFC cards and physical keys. Aqara is also working to add the HomeKey support to the U200 lock, which allows iOS users to unlock by simply tapping a compatible iPhone and Apple Watch. The U200 will be one of the first Matter-compatible locks to support HomeKey unlocking, and the Aqara team is sparing no time on developing and testing before delivering the optimized experiences2.
The U200 features a retrofit design, allowing for hassle-free installation on existing doors - without the need for extensive modification or renovation. Compatible with most doors in both Europe and North America, it attaches to existing lock mechanisms such as European cylinders (emergency function required) and deadbolts using one of the provided adapters3. The U200 intends to bring the modern keyless lifestyle to a broad array of homeowners and renters, while preserving the option to use traditional keys. Users also enjoy easy access sharing, remote access control, and real-time lock status updates for enhanced convenience and security.
The U200 lock runs on rechargeable Li-Ion batteries, while its wireless keypad can either be powered by a pack of four AAA batteries or wired to the existing doorbell wire (12V-24V DC power supply). Thanks to the power-efficient Thread protocol, the U200 lock features a battery life of up to 6 months between each charge4. Moreover, the wireless keypad boasts an IPX5 rating and withstands extreme heat and cold (-18℃/0℉ to 66℃/151℉), ensuring endurance under any climate.
As an integral part of a connected home, the U200 smart lock seamlessly works with other smart home accessories, allowing users to create a fully automated and customized smart home experience. For example, to disarm the home security system automatically when the U200 is unlocked by a family member, or to activate the indoor camera and the video doorbell after consecutive failed attempts to unlock the door. With three color options available for pre-order on Kickstarter, the U200 can fit into most home decor, making it the perfect addition to any home.
The Aqara Smart Lock U200 is now available for pre-order on Kickstarter at https://www.kickstarter.com/projects/aqara-u200/smartlock for those looking to be among the first to explore the latest in home access technologies.
- The U200 can be paired to the Aqara Home app using Bluetooth or the upcoming Aqara Hub M3. Compatibility with third-party Matter-enabled platforms (e.g., Amazon Alexa, Apple Home, Google Home, Samsung SmartThings, Home Assistant) is expected to roll out in waves, and may not be available by the shipment of pre-ordered units.
- HomeKey unlocking support is currently under development, and is expected to become available via a subsequent OTA update after the lock receives certain certification.
- Limitation applies. Please check the Kickstarter page or consult Aqara support for detailed guidelines on the U200 lock compatibility.
- The 6-month battery life is based on the assumption of 8 cycles of fingerprint/NFC unlocking and locking per day.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227373928/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom